Plus, news about Sumitomo Pharma, Gilead, Roche, Desentum, Inhibrx and Pila Pharma:
Roche's Ocrevus fails high-dose study: The Phase 3 study looking at a dose higher than the approved 600 mg of Ocrevus IV ...
↧
